Prosensa Therapeutics (Netherlands) a clinical-stage biopharmaceutical company focused on RNA-modulating therapeutics for Duchenne’s Muscular Dystrophy, Huntington’s disease and myotonic dystrophy, closed a $30.7M Series A financing. Participants include New Enterprise Associates, Abingworth Life Sciences Partners, Gimv, Idinvest Partners and MedSciences Capital.